Strategy anchored on early clinical development of proprietary assets with single-agent potential: Drive innovation with first-in-class ANKET ® NK-cell engager Platform Accelerate development of...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that its management will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare...

Findings reveal promising early signs that lacutamab may help alleviate some of the most distressing symptoms of cutaneous T cell lymphomas Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“...

Innate will receive 3m USD upfront plus up to 4.9m USD in conditional tranched investments from The Institute for Follicular Lymphoma Innovation (IFLI) Patients with R/R Follicular Lymphoma will be...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that abstracts related to lacutamab health-related quality of life and translational data from the...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today released its 2025 financial calendar: March 27, 2025: Publication of 2024 financial statements May 13, 2025...

IPH6501 is a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 and developed for B-NHL IPH6501 boosts NK cell proliferation and cytotoxicity, showing activity...

Jonathan Dickinson appointed Chief Executive Officer and Chairman of the Executive Board Encouraging initial FDA feedback received on lacutamab regulatory pathway Lacutamab health-related quality of...